SCHEDULEDDate confidence: SCHEDULEDGiven as scheduledHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all SCHEDULED pins77% CONFIDENCEOverall confidence: 77%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better17 days ago
Inovio's[1] filing acceptance release and later results set a PDUFA goal date of 30 October 2026.The FDA's PDUFA goal date for Inovio's INO-3107, a DNA medicine for adults with recurrent respiratory papillomatosis, is 30 October 2026 under the accelerated approval pathway.